Company: TVRD
Filing Date: 2025-03-11
Form Type: 10-K
Source: 0001558370-25-002705
Chunk: 4

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-03-11
Form: 10-K
Item: Item 10D
Chunk 4
---
Item 10. Directors, Executive Officers and Corporate Governance.

The following table sets forth information about our current executive officers and directors as of January 15, 2025.

​​​​​Name    Age    Position(s)Executive Officers      Christopher Posner 55 President, Chief Executive Officer and DirectorRyan Maynard 55 Chief Financial OfficerScott M. Terrillion 62 General Counsel, Secretary and Chief Compliance Officer​​​​​Non-Employee Directors      Martin Vogelbaum (1)(2)(3) 61 Chair of the Board of DirectorsJeffrey L. Ives, Ph.D. (1)(2)(3) 73 DirectorSusan Shiff, Ph.D. (2)(3) 63 DirectorLisa von Moltke, M.D.(3) 66 DirectorHelen M. Boudreau (1) 58 Director

(1) Member of the audit committee. 

(2) Member of the compensation committee. 

(3) Member of the nominating and corporate governance committee. 

​

Executive Officers

Christopher Posner has served as our President and Chief Executive Officer since November 2021 and has served as a member of our Board since August 2018. From July 2017 to October 2021, he served as the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Mr. Posner served as a director of Zevra Therapeutics, Inc. (formerly KemPharm, Inc.), a publicly traded rare disease therapeutics company, from November 2022 through April 2023. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University.

His extensive experience in global pharmaceutical management, sales and products provides him with the qualifications to serve on our Board.

Ryan Maynard has served as our Chief Financial Officer since September 2022. Prior to joining Cara, Mr. Maynard served as the Chief Financial Officer of LetsGetChecked, a global healthcare solutions company, from October 2019 to March 2022. Mr. Maynard previously served as the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company, from February 2018 to June 2019. Mr. Maynard